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Abstract An important task of human genetics studies is to accurately pre-
dict disease risks in individuals based on genetic markers, which allows for
identifying individuals at high disease risks, and facilitating their disease treat-
ment and prevention. Although hundreds of genome-wide association studies
(GWAS) have been conducted on many complex human traits in recent years,
there has been only limited success in translating these GWAS data into clini-
cally useful risk prediction models. The predictive capability of GWAS data is
largely bottlenecked by the available training sample size due to the presence
of numerous variants carrying only small to modest effects. Recent studies have
shown that different human traits may share common genetic bases. There-
fore, an attractive strategy to increase the training sample size and hence
improve the prediction accuracy is to integrate data of genetically correlated
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2 Cong Li et al.
phenotypes. Yet the utility of genetic correlation in risk prediction has not
been explored in the literature. In this paper, we analyzed GWAS data for
bipolar and related disorders (BARD) and schizophrenia (SZ) with a bivari-
ate ridge regression method, and found that jointly predicting the two phe-
notypes could substantially increase prediction accuracy as measured by the
AUC (area under the receiver operating characteristic curve). We also found
similar prediction accuracy improvements when we jointly analyzed GWAS
data for Crohn’s disease (CD) and ulcerative colitis (UC). The empirical ob-
servations were substantiated through our comprehensive simulation studies,
suggesting that a gain in prediction accuracy can be obtained by combining
phenotypes with relatively high genetic correlations. Through both real data
and simulation studies, we demonstrated pleiotropy as a valuable asset that
opens up a new opportunity to improve genetic risk prediction in the future.
Keywords Genetic risk prediction · Genome-wide association study ·
Pleiotropy · Ridge regression
1 Introduction
Predicting disease risks in individuals based on genetic markers, which is usu-
ally referred to as “genetic risk prediction”, is an important task in human
genetics studies [5]. Although hundreds of genome-wide association studies
(GWAS) have been conducted and many thousands of genomic regions have
been implicated for various human traits in recent years, these findings have
not been translated into clinically useful risk prediction models based on ge-
netic markers, which limits their potential impact on personalized disease pre-
vention and treatment. Most genetic risk prediction models, including those
used by direct-to-customer genetic testing companies, are constructed based on
a few significant (usually validated) single nucleotide polymorphisms (SNPs).
However, such SNPs typically account for only a small fraction of the total her-
itability and thus cannot provide satisfactory prediction accuracy [23]. A large
fraction of the genetic variances is not accounted by such genetic risk predic-
tions because they were “missing” in the SNPwise GWAS results [21]. Several
hypotheses have been put forward to explain the “missing heritability” [7],
including epistasis [4,17], undetected CNVs [10], and rare variants [6], among
others. However, it has also been suggested that much of the missing heritabil-
ity is in fact hidden among the numerous common genetic variants carrying
only small to modest effects [11,33,24]. Through a polygenic risk-score analysis
on GWAS data of schizophrenia (SZ) and bipolar disorder (BP), Purcell et al
[25] inferred that the genetic risk factors for SZ and BP may involve thousands
of common SNPs of very individually small effect sizes. Using a linear mixed
model, Yang et al [35] estimated that whole-genome common SNPs could ex-
plain about 45% of the human height variance. Lee et al [19] extended this
method to complex human diseases and also found that a substantial fraction
of the phenotypic variances could be explained by genotyped common SNPs.
In this manuscript, we refer to the proportion of phenotypic variance explained
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by all genotyped common SNPs as the “chip heritability” [36], denoted as h2.
These results suggest that, instead of building genetic prediction models
with only a few significant variants, a more sensible approach would be to
impose less stringent criteria on variant selection or even to build prediction
models using whole genome variants [3]. In this way, more variants with weak
effects can be used though at the expense of also including many variants that
do not affect the phenotype one way or the other, or even act in the opposite
effect direction. Following Makowsky et al [22], we refer to this class of meth-
ods as Whole Genome Prediction (WGP) methods. However, there is still a
significant gap between the prediction accuracy achieved and the genetic vari-
ance accounted by all common SNPs, even for the WGP methods [22]. These
authors also investigated several parameters that affect prediction accuracy
and showed that a substantial gain may be achieved by increasing the training
sample size, and using training samples that are more related to the testing
samples. Wray et al [34] also pointed out limited sample size as a bottleneck
to achieve accurate genetic risk predictions.
These studies suggest that, in the presence of numerous weak-effect variants
for most complex traits , one of the most effective ways to develop a more ac-
curate risk prediction model is to increase the size of the training sample. But
subject recruitment may be difficult and expensive. Alternatively, if another
phenotype shares some genetic variants that affect the primary phenotype of
interest, it might be possible to incorporate the available data for this corre-
lated phenotype in risk model developments. In this way, we can increase the
effective training sample size with the caveat that the additional samples are
not directly related to the primary phenotype of interest. Appropriate statis-
tical methods are needed to jointly analyze these distinct yet related data sets.
In fact, there is accumulating evidence suggesting that different complex
human traits are genetically correlated, i.e. multiple traits share common ge-
netic bases, which is also formally known as “pleiotropy”. In a systematic anal-
ysis of the open-access NHGRI catalog, 17% of the trait-associated genes and
5% of the trait-associated SNPs showed pleiotropic effects [27]. Vattikuti et al
[32] used a bivariate linear mixed model to analyze the Atherosclerosis Risk in
Communities GWAS and found significant genetic correlations between several
metabolic syndrome traits, including body-mass index, waist-to-hip ratio, sys-
tolic blood pressure, fasting glucose, fasting insulin, fasting trigylcerides, and
fasting high-density lipoprotein. Lee et al [20] extended this bivariate linear
mixed model so that it could deal with binary traits, e.g. presence or absence
of a disease. Andreassen et al [1] applied a “pleiotropic enrichment” method on
GWAS data of schizophrenia and cardiovascular-disease and showed that the
power to detect schizophrenia-associated common variants can be improved
by exploiting the pleiotropy between these two phenotypes. More recently, a
study on genome-wide SNP data for five psychiatric disorders in 33,332 cases
and 27,888 controls identified four significant loci (P < 5×10−8) affecting mul-
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tiple disorders, including two genes encoding two L-type voltage-gated calcium
channel subunits, CACNA1C and CACNB2 [28]. Results from the large scale
Collaborative Oncological Gene-environment Study also highlighted the exis-
tence of “carcinogenic pleiotropy”, i.e. the overlap between loci that confer
genetic susceptibility to multiple types of tumor [26].
All these findings are exciting because they imply that genetic correlation
are prevalent among complex human diseases and hence leveraging the genetic
correlations between phenotypes might be a promising strategy to improve
genetic risk prediction in the future. Although genetic correlations have been
extensively studied for association analyses [18,16], little attention has been
paid to their utility in genetic risk prediction. In this paper, we propose to use
a bivariate ridge regression method to leverage the genetic correlation between
two diseases in genetic risk prediction. We analyzed real GWAS data sets for
two pairs of related common diseases. We performed a comprehensive simu-
lation study on the utility of genetic correlation by investigating the gain of
prediction accuracy as a function of the strength of genetic correlation between
two traits. We also examined the effects of several other parameters such as
the “chip heritability” h2, the training sample size and the number/proportion
of causal SNPs.
2 Methods
In this study, four dbGap data sets were analyzed. We didn’t obtain the con-
sent from the participants because we downloaded the data indirectly from
database. Moreover, the data were analyzed anonymously. For two of the db-
Gap datasets, we obtained the approval of the institutional review board. For
the other two data sets, institutional review board approval is not required to
access the data sets.
Data Description
We downloaded a GWAS data set of bipolar and related disorders (BARD) and
a GWAS data set of schizophrenia (SZ) from the dbGaP database (https://
dbgap.ncbi.nlm.nih.gov). All the subjects were genotyped on the Affymetrix
Genome-Wide Human SNP Array 6.0 platform. See http://www.ncbi.nlm.
nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000017.v3.p1 and
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs000021.v3.p2 for more details. We merged the two data sets after re-
moving redundant subjects and collected the genotype data for subjects with
only European ancestry. The merged data set consists of 653 affected subjects
for BARD, 1170 affected subjects for SZ and 1403 controls. SNPs with mi-
nor allele frequency (MAF) smaller than 0.05 and missing rate greater than
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0.01 were excluded. The remaining missing genotypes were randomly drawn
from binomial distributions based on the allele frequencies at the given loci.
SNPs that failed the Hardy-Weinberg Equilibrium test (P < 0.0001) in either
BARD, SZ or control group were also excluded. We also performed linkage-
disequilibrium pruning so that every pair of SNPs within a 50-SNP window
had an R-squared value no greater than 0.8. After these procedures, 298,604
SNPs remained.
For the second pair of diseases, we downloaded a GWAS data set of Crohn’s
disease (CD) and a GWAS data set of ulcerative colitis (UC). The subjects
in the CD data set were genotyped on the ILLUMINA HumanHap300v1.1 plat-
form. See http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000130.v1.p1 for more details. UC subjects were genotyped on
either the ILLUMINA HumanHap300v2 or the HumanHap550v3 platform. See
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_
id=phs000345.v1.p1 for more details. Since the SNPs on the HumanHap300v1.1
platform are a subset of the SNPs on the other two platforms, we retained
only the HumanHap300v1.1 SNPs in all the data sets for further analysis.
In the CD data set, only subjects with non-Jewish, European ancestry were
included in analysis, which include of 515 unaffected subjects and 513 af-
fected subjects. The UC data set consists of 902 non-Hispanic, European an-
cestry, affected individuals. To have a genetically matched control data set
for UC, we downloaded all the Caucasian subjects that have genotypes from
the HumanHap300v1.1 SNPs from the ILLUMINA iControl database (http:
//www.illumina.com/science/icontroldb.ilmn). We performed principal
component analysis on the iControl samples and the UC samples. For each
UC sample, we selected an iControl sample with the smallest Euclidean dis-
tance between their first 20 principal components. SNPs that were overlapped
between all these data sets were used for analysis after excluding SNPs with
minor allele frequency smaller than 0.05 and missing rate greater than 0.01.
The remaining missing genotypes were randomly drawn from binomial distri-
butions based on the allele frequencies at the given loci. SNPs that failed the
Hardy-Weinberg Equilibrium test (P < 0.0001) in either data set were also
excluded. We also performed linkage-disequilibrium pruning so that every pair
of SNPs within a 50-SNP window had an R-squared value no greater than 0.8.
After these procedures, 241,649 SNPs remained.
Bivariate Ridge Regression
To take advantage of the pleiotropy, we used a bivariate ridge regression
method to predict jointly the status for two diseases. In fact, the bivariate
(or multivariate) ridge regression was motivated as a generalization of univari-
ate ridge regression to account for the “across regression” correlations when
multiple linear regressions are simultaneously considered [2,13]. Similar to the
relationship between the univariate ridge regression and the univariate linear
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mixed model, the bivariate ridge regression is also closely related to the bivari-
ate linear mixed model, which has been implemented to estimate the genetic
correlation between phenotypes recently [20]. Here we highlight this connec-
tion while we go through the formulation of bivariate ridge regression.
Consider the following bivariate linear mixed model[30]:
y(1) = X(1)β(1) + g(1) + e(1),
y(2) = X(2)β(2) + g(2) + e(2) (1)
where y(1) and y(2) are the two vectors of two phenotypes measured on n1
and n2 individuals, respectively. In this study, X
(1) and X(2) consist of only
a column of ones respectively, indicating that only the intercept is included
as fixed effect. In this case, β(1) and β(2) are simply the means of the two
phenotypes. In the rest of this paper, we assume that y(1) and y(2) are already
mean-subtracted for convenience. g(1) and g(2) are the genetic values for the
two phenotypes. e(1) and e(2) are the residuals. The genetic values g(1) and
g(2) are treated as random effects:
g(1) = G(1)u(1), g(2) = G(2)u(2) (2)[
u
(1)
j
u
(2)
j
]
∼ N (0,Σg) (3)
Σg =
[
σ2g1 ρgσg1σg2
ρgσg1σg2 σ
2
g2
]
(4)
where G(t) is the standardized genotype matrix for a total of p SNPs of
the training samples for the t-th phenotype. Specifically, let B and b be
the two alleles at the j-th locus and fj be the frequency of the B allele,
then G
(t)
ij takes a value of −2fj/
√
2fj(1− fj)p, (1 − 2fj)/
√
2fj(1− fj)p or
2(1− fj)/
√
2fj(1− fj)p if the genotype of the i-th individual at the j-th lo-
cus is bb, Bb or BB, respectively. u
(1)
j and u
(2)
j are the random effects of the
j-th locus for the two phenotypes and ρg measures the strength of genetic
correlation between the two phenotypes. We also assume the residuals follow
a multivariate normal distribution:[
e(1)
e(2)
]
∼ N (0,Σe) (5)
Σe =
[
σ2e1In1 0
0 σ2e2In2
]
. (6)
In Lee et al.[20], the random effects u(1), u(2), e(1) and e(2) were integrated
out and the average information restricted maximum likelihood (AI-REML)
algorithm [12] was used to estimate the variance parameters σ2g1 , σ
2
g2 , ρg, σ
2
e1 ,
σ2e2 . ρg measures the genetic correlation between the two phenotypes whereas
Improving genetic risk prediction by leveraging pleiotropy 7
the other four variance parameters can be used to calculate the “chip” heri-
tability or “variance explained by SNPs” for the two phenotypes. However, our
focus here is not to estimate the “chip heritability” or the genetic correlation
but to predict the phenotypes. Therefore we are more interested in estimating
the random effects: u(1) and u(2). Given a certain set of variance parameters
σ2g1 , σ
2
g2 , ρg, σ
2
e1 and σ
2
e2 , the posterior means of the random effects u
(1) and
u(2) can be written out as:[
uˆ(1)
uˆ(2)
]
= ((Σg ⊗ Ip)−1 + G′Σ−1e G)−1G′Σ−1e
[
y(1)
y(2)
]
(7)
where G =
[
G(1) 0
0 G(2)
]
and ⊗ stands for the Kronecker product. After some
rearrangements, we can see that this is essentially equivalent to the solution
to a bivariate ridge regression given a certain set of regularization parameters:[
uˆ(1)
uˆ(2)
]
= (K⊗ Ip + G′G)−1G′
[
y(1)
y(2)
]
(8)
where K = (1− ρ2g)−1
[
σ2e1/σ
2
g1 −ρgσ2e2/(σg1σg2)
−ρgσ2e1/(σg1σg2) σ2e2/σ2g2
]
is the “ridge ma-
trix” as defined in Brown and Zidek[2].
We note that directly calculating Eq. (8) is infeasible because it involves
inversion of a 2p by 2p matrix where p is total number of SNPs, which could be
in the order of 106 in a typical GWAS. Therefore we used the matrix inversion
lemma to rearrange it as:
[
uˆ(1)
uˆ(2)
]
= (K−1 ⊗ Ip)G′[I(n1+n2) + G(K−1 ⊗ Ip)G′]−1
[
y(1)
y(2)
]
(9)
where K−1 =
[
σ2g1/σ
2
e1 ρgσg1σg2/σ
2
e1
ρgσg1σg2/σ
2
e2 σ
2
g2/σ
2
e2
]
. Now we only need to evaluate
the inverse of a matrix of dimension (n1 + n2) by (n1 + n2), which is usually
in the order of 103. Given the estimates of the random effects uˆ(1) and uˆ(2)
and two sets of validation individuals with standardized genotype matrix G
(1)
v
and G
(2)
v , the predicted values for the two phenotypes are given by:
yˆ(1) = G(1)v uˆ
(1), yˆ(2) = G(2)v uˆ
(2) (10)
The solution of the bivariate ridge regression depends on four regularization
parameters. To alleviate the computational burden of tuning the regulariza-
tion parameters, we impose the constraint that σe1 = σe2 , which leads to a
symmetric “ridge matrix” K and hence a symmetric K−1. Then we can repa-
rameterize K−1 as
[
λ1 ρg
√
λ1λ2
ρg
√
λ1λ2 λ2
]
. As a result, we only need to tune
three regularization parameters λ1, λ2 and ρg. λ1 and λ2 control the shrinkage
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level of genetic effects for the two phenotypes whereas ρg controls the correla-
tion between the genetic effects between the two phenotypes. In order to find
the optimal regularization parameters, we perform grid searches with λ1 and
λ2 ranging from a very small number λmin to a very large number λmax and
ρg ∈ [0, 1). In the real data analysis, the parameter values that give the highest
cross-validation mean AUC for each phenotype were chosen. In the simulation
studies, the parameter values that give the highest AUC in the validation data
for each phenotype were chosen.
We classify the validation individuals into affected ones and unaffected ones
by dichotomizing the predicted values with a grid of threshold values ranging
from the largest predicted value to the smallest predicted value and obtain
the receiver operating characteristic curve by evaluating the sensitivity and
specificity at each threshold value. Then we evaluate the area under receiver
operating characteristic curve (AUC) as a measure of the prediction accuracy.
In the bivariate ridge regression, we used cross-validation to tune the reg-
ularization parameters instead of trying to estimate the parameters from the
data as in [20]. There are primarily two reasons: 1) the AI-REML algorithm
that Lee et al. used in [20] sometimes fails to converge, for example on the
CD-UC data set. 2) The estimated parameters are based on normality assump-
tions and henceforth may not be optimal for predicting binary phenotypes.
Simulation Study
In order to examine the relationship between the gain of predictive power and
the level of genetic correlation between two diseases, we performed the follow-
ing simulation studies based on the classical liability threshold model [8] to
simulate the case-control data. Specifically, given a desired sample size N , the
total number of SNPs p, the proportion of cases in the case-control data P and
the disease prevalence Q, genotypes of a cohort of at least NP/Q individuals
were generated as follows: first, the MAF of p SNPs were uniformly drawn
from [0.05, 0.5]; then the genotypes (the number of minor allele copies) for the
NP/Q individuals at each SNP were drawn from a binomial distribution of
size two and the probability of success being the MAF of the corresponding
SNP.
After the genotypes were generated, m casual SNPs were randomly chosen
with each causal SNP carrying a per-minor-allele effect drawn from a normal
distribution with zero mean and variance of h
2
(1−h2)fj(1−fj)m where h
2 is the
desired level of variance explained by all SNPs on the liability scale and fj is
the MAF of the corresponding causal SNP. Then the environmental effect on
the liability scale for each individual was independently drawn from a stan-
dard normal distribution (zero mean and unit variance). Then, we obtained
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the liability for each individual by adding up the genetic effects conferred by
all causal SNPs and environmental effect. Once the liabilities were obtained,
individuals with liabilities greater than the 1 − Q quantile were classified as
cases and the others classified as controls. Then NP cases and N(1−P ) con-
trols were randomly drawn from the cohort. When simulating data for two
diseases simultaneously, the two data set were simulated from two disjoint co-
horts. The MAF for each SNP was the same for the two cohorts. A total of
m′ causal SNPs were chosen to be shared between the two diseases to mimic
the shared genetic basis between them. We assume shared causal SNPs have
a correlation of 0.8 between their liability scale effect sizes in the two diseases.
In our simulation studies, we set the sample size N at 1,000 or 2,000. The
number of causal SNPs m was chosen to be 1,000 or 2,000. P was fixed at 0.5
and K was fixed at 0.05. We assumed the two diseases had the same number
of casual SNPs. We varied the proportion of the causal SNPs that were shared
between the two diseases γ = m′/m from 0 to 1 to model different levels of ge-
netic correlation and investigated the gain of predictive power under different
settings. We also investigated the effects of unequal sample size and unequal
h2 between the two diseases.
3 Results
Results from Real Data
We analyzed GWAS data for bipolar and related disorders (BARD) and schizophre-
nia (SZ) that we downloaded from the dbGaP database (https://dbgap.
ncbi.nlm.nih.gov). After pre-processing (see Methods), the combined data
set consisted of 3,226 individuals (653 cases for BARD, 1,170 cases for SZ and
1,403 controls) with genotypes at 298,604 SNPs. In order to organize two case-
control data sets for the two diseases, we randomly partitioned the controls
into two disjoint sets of individuals and assigned each set to one of the dis-
eases. We partitioned the control individuals so that the proportions of cases
for the two data sets were approximately equal, i.e. we assigned 505 controls to
BARD and 898 controls to SZ. The random partitioning was repeated 50 times.
We then used the bivariate ridge regression method [2] described above to
predict jointly the disease status for BARD and SZ using this data set. Pre-
diction performance was evaluated through five-fold cross-validation, i.e., the
data were randomly partitioned into five equal-sized folds and four of them
were used as the training set and the other one was used as the validation set
each time. We calculated the mean AUC (area under the receiver-operating-
characteristic curve) for the five folds to measure prediction performance. For
comparison, we also evaluated prediction performance of three other predic-
tion methods: univariate ridge regression, SVM (support vector machine) [9]
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with linear kernel, and LASSO (least absolute shrinkage and selection opera-
tor) [31] that treat each disease separately (Figure 1). Note that the bivariate
ridge regression method we used is a direct generalization of the univariate
ridge regression (see Methods). Therefore the utility of pleiotropy can be best
demonstrated through the comparison between the two approaches. Indeed,
the bivariate ridge regression method performed better than the univariate
ridge regression for both BARD and SZ. We also note that the gain of AUC
of BARD (0.041) was much larger than that of SZ (only 0.013), probably as
a result of the sample size difference between the two diseases. SVM also per-
formed better than univariate ridge regression, but it was still outperformed
by bivariate ridge regression in BARD (with an AUC of 0.031) although in SZ
it performed better than bivariate ridge regression by 0.016. LASSO, which
prefers a sparse genetic architecture with a small number of major (strong
effect) SNPs, did not perform well for both diseases.
BVR(0.587) UVR(0.546) SVM(0.556) LASSO(0.522)
0.
50
0.
55
0.
60
0.
65
BARD
A
U
C
BVR(0.613) UVR(0.600) SVM(0.629) LASSO(0.541)
0.
50
0.
55
0.
60
0.
65
Schizophrenia
A
U
C
Fig. 1 Prediction accuracy of different methods on the BARD-SZ data. “BVR” and “UVR”
stand for bivariate ridge regression and univariate ridge regression respectively. The numbers
in the brackets are the mean AUCs achieved by each method in the 50 repeats.
To evaluate whether the improvement was the result of the genetic correla-
tion between BARD and SZ or an artificial effect of the bivariate ridge regres-
sion method, we randomly selected 25%, 50%, 75% and all of the SNPs and
shuffled their identities in the BARD samples while keeping the SNP identities
unchanged in the SZ samples. This led to reduced genetic correlation between
BARD and SZ and consequently reduced improvement of prediction accuracy
for the bivariate ridge regression (Figure 2). In particular, when all the SNPs
were shuffled, the performance of bivariate ridge regression was almost the
same as univariate ridge regression, confirming that the gain of prediction ac-
curacy of the bivariate ridge regression indeed came from specific SNP, and
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thus the genetic correlation between the two phenotypes.
0% 25% 50% 75% 100% UVR
0.
50
0.
55
0.
60
0.
65
BARD
A
U
C
0% 25% 50% 75% 100% UVR
0.
50
0.
55
0.
60
0.
65
Schizophrenia
A
U
C
Fig. 2 Prediction accuracy of the bivariate ridge regression after shuffling the SNP identities
and of ridge regression. Red plots represent the results of bivariate ridge regression and blue
plots represent those of ridge regression. The percentage below each red plot represents the
fraction SNPs that were shuffled.
We also did the same analysis on a GWAS data set for Crohn’s disease (CD)
and a GWAS data set for ulcerative colitis (CD) obtained from the dbGap
database. The CD data set consists of 515 unaffected subjects and 513 affected
subjects with non-Jewish European ancestry and the UC data set consists of
902 affected subjects with non-Jewish European ancestry. Because there are no
control samples for the UC data set, we obtained 902 samples from the Illumina
iControl database (http://www.illumina.com/science/icontroldb.ilmn)
that were genetically matched with the UC samples to minimize the con-
founding effect of potential population stratification (see Methods). After pre-
processing (see Methods), we obtained a data set consisting of 513 affected
subjects for CD, 515 unaffected subjects for CD, 902 affected subjects for UC
and 902 unaffected subjects for UC with genotypes for 241,649 SNPs. As op-
posed to the BARD and SZ data set, the control samples for CD and UC were
fixed instead of being randomly partitioned.
Prediction accuracies of different methods on the CD-UC data set were
also evaluated through five-fold cross-validation, with the cross-validation re-
peated 50 times. The results are shown in Figure 3. Similar to the results for
the BARD-SZ data, bivariate ridge regression performed better than univari-
ate ridge regression in both diseases. Moreover, the increase of AUC for CD,
which has a smaller sample size, was larger than that of UC (0.055 versus
0.019). SVM also outperformed univariate ridge regression in both diseases
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but was outperformed by bivariate ridge regression in CD.
BVR(0.663) UVR(0.608) SVM(0.646) LASSO(0.585)
0.
55
0.
60
0.
65
0.
70
CD
A
U
C
BVR(0.620) UVR(0.601) SVM(0.635) LASSO(0.635)
0.
55
0.
60
0.
65
0.
70
UC
A
U
C
Fig. 3 Prediction accuracy of different methods on the CD-UC data. “BVR” and “UVR”
are defined as in Figure 1. The numbers in the brackets are the mean AUCs achieved by
each method in the 50 repeats.
Similar to the BARD-SZ data set, we performed random shuffling of the
identities of the SNPs in the CD samples while keeping their identities in the
UC samples. The results are shown in Figure 4. As expected, the improvement
of prediction accuracy of bivariate ridge regression also decreases as the frac-
tion of SNPs increases and eventually diminishes when all SNPs are shuffled.
Results from Simulation Study
We simulated data sets for two genetically correlated diseases to evaluate the
utility of genetic correlation in genetic risk prediction. We simulated a total
of p = 20, 000 SNPs. We let the sample size N to be 1000 or 2000. The num-
ber of causal SNPs m was also chosen to be 1000 or 2000. We assumed the
two traits had the same number of casual SNPs. We varied the proportion
of the causal SNPs that were shared between the two diseases γ from 0 to 1
to mimic different levels of genetic correlation. We assumed that the shared
causal SNPs had a correlation of 0.8 between their effect sizes on the two
diseases. Our empirical results suggest that the realized genetic correlation is
approximately 0.8γ under this setup (results not shown). We simulated two h2
levels (on liability scale, see [19]): 0.3 and 0.6. Disease prevalence was set to be
0.05 and equal numbers of cases and controls were drawn from the simulated
population. The simulations were repeated for 25 times in each scenario. In
each repeat, a training set and a validation set were independently generated
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C
Fig. 4 Prediction accuracy of the bivariate ridge regression after shuffling the SNP identities
and of ridge regression. Red plots represent the results of bivariate ridge regression and blue
plots represent those of the ridge regression. The percentage below each red plot represents
the fraction SNPs that were shuffled.
and were used to evaluate the prediction accuracies of bivariate ridge regres-
sion and univariate ridge regression.
We first considered the scenario where both diseases had the same number
of samples and the same h2 level. The results for m = 1000 are shown in
Figure 5 and the result for m = 2000 are shown in Figure S1. As expected,
when the genetic correlation between the two diseases was zero, the prediction
accuracy of bivariate ridge regression was almost the same as univariate ridge
regression. As the genetic correlation increased, the AUC for bivariate ridge
regression also increased and the improvement over univariate ridge regression
became quite noticeable as long as γ ≥ 0.5, which corresponds to a genetic
correlation of approximately 0.4.
We also examined the case when the sample sizes (Figure 6 and Figure S2)
or the h2 levels (Figure 7 and Figure S3) were different between the two traits.
When the sample sizes were different but the h2 levels were the same between
the two diseases, the prediction accuracy of the disease with the smaller sam-
ple size improved more than that of the disease with the larger sample size by
joint modeling, which echoes with the results from the real data analysis.
4 Discussion
Genetic risk prediction is a challenging task due to the existence of numerous
weak-effect variants and is also bottlenecked by the available sample size of
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Fig. 5 Simulation results for the case when the two diseases have equal sample sizes and h2
levels and m = 1000. “BVR” and “UVR” are defined as in Figure 1. Two h2 levels (0.3 and
0.6) and two sample sizes (1000 and 2000) were simulated. The proportion of shared causal
SNPs, γ was varied from 0 to 1 with an increment of 0.25. The numbers below the UVR box
plots are the sample sizes. Following the UVR box plots are the box plots representing the
results of BVR with the same sample sizes at different γ values (below the BVR box plots).
GWAS. A promising yet under-appreciated strategy to increase the effective
training sample size and thus to improve prediction accuracy is to integrate dis-
eases that are genetically correlated. In this paper we performed a systematic
investigation of the utility of genetic correlation in genetic risk prediction using
a bivariate ridge regression method. In the real data analysis, we demonstrated
that gain of predictive power can be achieved by using the genetic correlation
between phenotypes. In the simulation study, the results confirmed our find-
ings in the real data, as well as offered us insights into the relationship between
gain of prediction accuracy and the level of genetic correlation between two
phenotypes. These results can provide important guide for researchers to make
productive use of pleiotropy while developing disease risk prediction models
in the future.
In the real data and simulation studies, we found that the prediction accu-
racy of the disease with the smaller sample size benefited more from the joint
modeling than that of the disease with the larger sample size. The possible
reason is that when jointly modeling the two data sets, the larger data set con-
tains more information or statistical evidence about the genetic effects shared
by the two diseases than the smaller data set, and therefore more information
can be borrowed from the larger data set to the smaller data set than the op-
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Fig. 6 Simulation results for the case when the two diseases have unequal sample sizes
and equal h2 levels and m = 1000. “BVR” and “UVR” are defined as in Figure 1. One of
the diseases has 2000 samples and the other has 1000 samples. Two h2 levels (0.6 and 0.3)
were simulated. The proportion of shared causal SNPs, γ was varied from 0 to 1 with an
increment of 0.25. The numbers below the UVR box plots are the h2 levels. Following the
UVR box plots are the results of BVR with the same h2 levels at different γ values (below
the BVR box plots).
posite way. In the simulation studies, we also observed that when the sample
sizes were the same but the h2 levels were different, joint modeling offered
more benefit to the low-heritability disease than that of the high-heritability
disease. A similar explanation can be made: the high-heritability disease data
set can provide stronger statistical evidence about the genetic effects shared
by the two diseases than the low-heritability disease. Note that the two ex-
planations are based on the simulation setup that the number of associated
SNPs is the same for the two diseases, all the SNPs are independent, and the
genetic effects are randomly distributed among the causal SNPs.
To our knowledge, only Hartley et al [14,15] have studied pleiotropy in ge-
netic risk prediction to date. However, our study is distinct from theirs in two
aspects. Firstly, Hartley et al. focused on methodological development whereas
our study emphasizes the utility of genetic correlation using real GWAS data
sets. In fact, our study is the first one to demonstrate a substantial contribu-
tion of genetic correlation to prediction accuracy on real data. Secondly, their
method requires that all the phenotypes of interest are observed on all individ-
uals, which limits its applications. In contrast, we consider the case where two
phenotypes are observed on two disjoint sets of individuals. Not only does this
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Fig. 7 Simulation results for the case when the two diseases have equal sample sizes and
unequal h2 levels and m = 1000. “BVR” and “UVR” are defined as in Figure 1. One of
the diseases has h2 = 0.6 and the other has h2 = 0.3. Two sample sizes (2000 and 1000)
were simulated. The proportion of shared causal SNPs, γ was varied from 0 to 1 with an
increment of 0.25. The numbers below the UVR box plots are the sample sizes. Following
the UVR box plots are the results of BVR with the same sample sizes at different γ values
(below the BVR box plots).
allow more GWAS data sets to be integrated, we can expect much more im-
provement of the predictive ability since the sample size is effectively increased
by combining the data for the two phenotypes whereas there is no increase in
the sample size in the scenario considered by Hartley and colleagues. In addi-
tion, even when we have phenotype information from multiple traits for each
study subject, the bivariate mixed effect model may not appropriately accom-
modate specific, sometimes complex, ascertainment schemes used to collect
the GWAS samples. This may lead to potential biases and reduced prediction
accuracy, e.g. causing some shared genetic effects between the two traits to be
cancelled out.
Solovieff et al [29] pointed out several sources of spurious pleiotropy. One is
sample ascertainment bias. In our real data examples, each “case” individual
is affected by only one disease and the controls are not shared by the two
diseases. Therefore, it is unlikely that our study is affected by ascertainment
bias. Another source is misdiagnosis, e.g. people with schizophrenia may be
misclassified as bipolar disorder. However they also noted that the misclassi-
fication rate has to be very high to generate a substantial genetic correlation,
which suggests the gain of prediction accuracy in our results may still primar-
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ily be a result of the true genetic correlation between the two diseases.
The method that we used to jointly predict two phenotypes is a bivari-
ate generalization to the ridge regression. Although the comparison between
bivariate ridge regression and univariate suggests that pleiotropy can indeed
substantially contribute to genetic risk prediction, we do note that there is
also a need to develop better methods for joint prediction of multiple pheno-
types. For example, SVM always does better than univariate ridge regression.
Development of such methods that jointly predict multiple phenotypes is an
important future task. In this study, we demonstrated the utility of pleiotropy
through two pairs of diseases that are known to share a lot of common genetic
bases. Another important future task is to comprehensively examine the ge-
netic correlations between other complex human diseases and their utility in
risk prediction.
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